GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » ROE % Adjusted to Book Value

PCI Biotech Holding ASA (OSL:PCIB) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA ROE % Adjusted to Book Value?

PCI Biotech Holding ASA's ROE % for the quarter that ended in Jun. 2024 was 0.00%. PCI Biotech Holding ASA's PB Ratio for the quarter that ended in Jun. 2024 was 2.20. PCI Biotech Holding ASA's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 0.00%.


PCI Biotech Holding ASA ROE % Adjusted to Book Value Historical Data

The historical data trend for PCI Biotech Holding ASA's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA ROE % Adjusted to Book Value Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -5.91 -12.79 -48.40 -21.07

PCI Biotech Holding ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.32 -29.59 -27.68 - -

Competitive Comparison of PCI Biotech Holding ASA's ROE % Adjusted to Book Value

For the Biotechnology subindustry, PCI Biotech Holding ASA's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's ROE % Adjusted to Book Value falls into.



PCI Biotech Holding ASA ROE % Adjusted to Book Value Calculation

PCI Biotech Holding ASA's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-42.13% / 2.00
=-21.07%

PCI Biotech Holding ASA's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 2.20
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines